Vascepa is an anti-hyperlipidemic drug owned by Amarin Pharms. It contains the active ingredient icosapent ethyl. The drug was first authorized for market use on 26 July 2012. Vascepa is available in capsule form for oral administration.
The generic version of Vascepa might be available after 28 June, 2033. The generic release date is determined by the expiry of the drug's last patent, in this case, US11369582 titled 'Methods of reducing the risk of cardiovascular events in a subject', which is set to expire on 28 June, 2033. Therefore, Vascepa generic may hit the market after this date.
Vascepa is primarily used to treat high levels of triglycerides, a type of fat found in the blood. It is often used as an adjunct to statin therapy to reduce the risk of cardiovascular events in adult patients with elevated triglyceride levels and other risk factors such as diabetes mellitus, established cardiovascular disease, and atrial fibrillation or atrial flutter. Vascepa works by reducing triglycerides and LDL-C (bad cholesterol) levels in the blood while not raising LDL-C levels when administered with statin therapy.
Vascepa has a total of 70 drug patents of which the last to expire is US11369582 titled 'Methods of reducing the risk of cardiovascular events in a subject'. This patent is set to expire on 28 June, 2033. Therefore, Vascepa generic may be available after this date. Below are the details of the patent: